Prognostic factors in multiple myeloma.
Tricot
Guido
G
University of Arkansas for Medical Sciences, AR, USA.
D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000096:biosynthesis / Q000235:genetics; D002869:Chromosome Aberrations; D016503:Drug Delivery Systems; D020869:Gene Expression Profiling; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007167:Immunotherapy; D007621:Karyotyping; D009101:Multiple Myeloma / Q000235:genetics / Q000401:mortality* / Q000601:surgery / Q000628:therapy; D009363:Neoplasm Proteins / Q000096:biosynthesis / Q000235:genetics; D015514:Oncogene Proteins, Fusion / Q000096:biosynthesis / Q000235:genetics; D018579:Patient Selection; D011379:Prognosis; D014178:Translocation, Genetic
D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D009363:Neoplasm Proteins; D015514:Oncogene Proteins, Fusion